When is it time to bid farewell to anticoagulation?

Decisions about antithrombotic therapy in cancer patients at the end of life can be challenging. This cohort study examined prescribing behaviour and outcomes relating to antithrombotic therapy in this patient group, finding that deprescribing was uncommon. Greater awareness of this neglected but high-risk aspect of patient care is required along with interventions to enable shared decision-making in this setting. Commentary on: Aldridge et al. Antithrombotic therapy in patients with cancer at the end of life and associated clinical outcomes: a cohort study using population-linked routinely collected data. Br J Haematol 2025;207:2080-2090.